A Comparison Between Sars-Cov-1 and Sars-Cov2: An Update on Current Covid-19 Vaccines Publisher Pubmed



Abdolmaleki G¹ ; Taheri MA¹ ; Paridehpour S¹ ; Mohammadi NM^{1, 2} ; Tabatabaei YA¹ ; Mousavi T^{3, 4} ; Amin M^{1, 2} Show Affiliations
Source: DARU# Journal of Pharmaceutical Sciences Published:2022

Abstract

Since the outbreak of the novel coronavirus disease 2019 (COVID-19) in Wuhan, China, many health care systems have been heavily engaged in treating and preventing the disease, and the year 2020 may be called as “historic COVID-19 vaccine breakthrough”. Due to the COVID-19 pandemic, many companies have initiated investigations on developing an efficient and safe vaccine against the virus. From Moderna and Pfizer in the United States to PastocoVac in Pasteur Institute of Iran and the University of Oxford in the United Kingdom, different candidates have been introduced to the market. COVID-19 vaccine research has been facilitated based on genome and structural information, bioinformatics predictions, epitope mapping, and data obtained from the previous developments of severe acute respiratory syndrome coronavirus (SARS-CoV or SARS-CoV-1) and middle east respiratory syndrome coronavirus (MERS-CoV) vaccine candidates. SARS-CoV genome sequence is highly homologous to the one in COVID-19 and both viruses use the same receptor, angiotensin-converting enzyme 2 (ACE2). Moreover, the immune system responds to these viruses, partially in the same way. Considering the on-going COVID-19 pandemic and previous attempts to manufacture SARS-CoV vaccines, this paper is going to discuss clinical cases as well as vaccine challenges, including those related to infrastructures, transportation, possible adverse reactions, utilized delivery systems (e.g., nanotechnology and electroporation) and probable vaccine-induced mutations. Graphical abstract: [Figure not available: see fulltext.] © 2022, The Author(s), under exclusive licence to Tehran University of Medical Sciences.